On the other hand, pivotal SSA studies included only patients with Ki-67 <10%, and small series indicate minimal effect in patients with G3 tumours (McGarrah et al. 2020, Lithgow et al. 2021, Merola et al. 2021). The gene discussed is MKI67; the disease is neoplasm.